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Introduction 
Mitochondrial diseases are a group of rare inherited disorders characterized by extreme phenotypic 
heterogeneity that can be transmitted by any mode of inheritance, with hitherto no effective therapy 
options. The recent evaluations of Next Generation Sequencing for mitochondrial disorders have 
shown that this methodology is more likely to provide a diagnosis, being quicker and cheaper.  
Our group, pioneer in the study of these disorders in our country, has been studying several 
patients with suspicious diagnosis of mitochondrial disorders. The biochemical and molecular 
approach used, allowed the characterization of many of these patients, however, some of them still 
remain without molecular diagnosis. 
 
Objectives 
The overall aim of our research project* was to develop a Next Generation Sequencing strategy to 
identify nuclear disease causing-mutations in patients suspicious of mitochondrial disorders but 
without molecular etiology. 
 
Methods 
Next Generation Sequencing was performed in a MiSeq Illumina instrument using a custom 
mitochondrial gene panel with around 200 genes involved in mitochondria metabolism. Libraries 
were prepared using SureSelect QXT target enrichment system from Agilent.  
  
Results 
Until now, we analyzed 20 patients, identifying disease related mutations in six of them. These 
mutations were confirmed by Sanger Sequencing in the index cases and in their relatives.  
Our project is ongoing and the patients undiagnosed after this first approach will be further selected 
for Whole Exome Sequencing. 
 
Discussion and Conclusion 
This study is contributing to i) identify the pathogenic mutations in the studied patients (6/20 – 30%), 
ii) expand the mutational spectrum in the etiology of these disorders, and iii) propose an accurate 
genetic counseling.  
Custom design panels have been widely used for molecular heterogeneous disorders however, the 
development of this panel will be innovative in our country strengthening our center as a national 
reference for the study and research of mitochondrial disorders. 
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